Dr Vivek Subbiah speaks to ecancer at the WIN 2019 Symposium in Paris about RET inhibition in RET aberrant cancers.

He explains that RET is an oncogenic driver seen in multiple cancers, most commonly lung cancers.

Dr Subbiah discusses various RET inhibitors with an important one being including BLU-667 which, following study, has been granted two US breakthrough designations.

Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php

свернуть